|

Trastuzumab Deruxtecan Clinical Trials

52 actively recruiting trials across 21 locations

No change since May 2026

Also known as: A1811, DS-8201, DS-8201a, DS-8201a (trastuzumab derextecan), DS-8201a, Enhertu +15 more

Pipeline

Phase 1: 6Phase 2: 20Phase 3: 10Phase 4: 2Phase 1/2: 6

Top Sponsors

  • Daiichi Sankyo7
  • AstraZeneca7
  • National Cancer Institute (NCI)5
  • Memorial Sloan Kettering Cancer Center2
  • Jeeyun Lee2

Indications

  • Cancer52
  • Breast Cancer28
  • Metastatic Breast Cancer9
  • Metastatic Malignant Solid Neoplasm4
  • HER2-positive Breast Cancer4

Other18 trials

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
Phase 2
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Phase 3
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1
Basket Study for Oligo-metastatic Breast Cancer
Phase 2
DESTINY Breast Respond HER2-low Europe
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
Phase 2
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Phase 2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Phase 2
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Phase 2
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
Phase 4
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Phase 2
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2
Trastuzumab Deruxtecan in Advanced Breast Cancer
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Phase 1/2

New Haven, Connecticut4 trials

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

Yale Cancer Center

SNV1521 in Participants With Advanced Solid Tumors

Smilow Cancer Hospital at Yale New Haven

Phase 1
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Yale Cancer Center

Phase 3
Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Yale University

Phase 2

Boston, Massachusetts4 trials

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 1/2
Scalp Cooling in MBC

Brigham and Women's Hospital

Phase 2
TRUDI: TDXD+Durva in HER2+/Low IBC

Brigham and Women's Hospital

Phase 2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Birmingham, Alabama3 trials

DESTINY-PANTUMOUR04

Research Site

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

University of Alabama

Phase 2
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California3 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

City of Hope Medical Center

Phase 4
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

City of Hope Comprehensive Cancer Center

Phase 2

Anchorage, Alaska2 trials

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Research Site

Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Alaska Oncology & Hematology, LLC

Phase 3

Phoenix, Arizona2 trials

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Mayo Clinic-Arizona

Phase 1/2
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Mayo Clinic Hospital in Arizona

Phase 1

Houston, Texas2 trials

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

MD Anderson Cancer Center

Phase 1/2
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

M D Anderson Cancer Center

Phase 1

Daphne, Alabama1 trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Southern Cancer Center (SCC) ( Site 8000)

Phase 3

Scottsdale, Arizona1 trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Research Site

Phase 3

Tucson, Arizona1 trial

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Research Site

Phase 3

Fullerton, California1 trial

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

St. Joseph Heritage Healthcare

Phase 2

La Jolla, California1 trial

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Scripps Clinic

Phase 3

Newport Beach, California1 trial

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Research Site

Phase 1

Sacramento, California1 trial

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

University of California Davis Comprehensive Cancer Center

Phase 1/2

Santa Monica, California1 trial

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Fort Lauderdale, Florida1 trial

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Broward Health Medical Center

Phase 3

Miami Beach, Florida1 trial

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Mount Sinai Medical Center

Phase 3

Tampa, Florida1 trial

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Moffitt Cancer Center

Phase 2

Ann Arbor, Michigan1 trial

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

University of Michigan (Data Collection Only)

Phase 2

St Louis, Missouri1 trial

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Washington University School of Medicine

Phase 1

New York, New York1 trial

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.